Shockwave is committed to partnering with clinicians to develop robust clinical and economic evidence for IVL. We have completed and/or are in the process of developing compelling evidence for the use of the technology across all peripheral vessels, from the renals on down to the feet
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.